Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-Week Multicentre Randomised Double-Blind Trial of Psilocybin in Alcohol Use Disorder
2021-006200-33Phase 2Terminated
- Sponsor
- Clairvoyant Therapeutics Inc.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol use disorder (AUD) comparing Psilocybin 25 mg with Placebo (2 arms). Primary endpoint: Number of heavy drinking days during 8-week treatment period. Started Jun 2022; status: terminated.
02
Drugs
psilocybin
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on 2021-006200-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006200-33.